Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use

University of Iowa · NCT06489249

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–24 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
24
US sites recruiting
2
Study start
August 15, 2024
Record last updated
December 15, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.

Being studied: Placebo; Salsalate 750 MG Oral Tablet [DISALCID]

Conditions: Electronic Cigarette Use; Endothelial Dysfunction; Inflammation

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • 18 - 24 years of age
  • no history of e-cigarette use (control) OR current with 6 months or more history of e-cigarette use (chronic use).

Exclusion Criteria

  • tobacco cigarette use (current or history of)
  • use of stimulant drugs
  • skin diseases
  • cardiovascular disease
  • diagnosed or suspected hepatic or metabolic disease including diabetes
  • statin or other cholesterol-lowering medication
  • antihypertensive medication
  • current pregnancy or breastfeeding
  • blood pressure greater than or equal to 140mmHg systolic and/or greater than or equal to 90mmHg diastolic
  • allergy to materials used during the experiment
  • known allergies to salsalate or other study drugs

Recruiting US locations

  • Iowa Bioscience Innovation Facility

    Iowa City, IA 52242

    Site contact: Anna Stanhewicz, P.h.D · 319-467-1732 · anna-stanhewicz@uiowa.edu

  • University of Iowa

    Iowa City, IA 52242

    Site contact: Anna Stanhewicz, PhD · 319-467-1732 · anna-stanhewicz@uiowa.edu

Study contacts (from the official record)

  • Anna Stanhewicz, PhD · 3194671732 · anna-stanhewicz@uiowa.edu
Role of Inflammation in Vascular Phenotype Associated With… (NCT06489249) | Bored Studies